miRNA in type 2 diabetes

被引:0
作者
Szweda, Nikola [1 ,2 ]
Laczmanski, Lukasz [3 ]
机构
[1] Med Univ Silesia, Fac Med, Chair Internal Med Diabetol & Nephrol Zabrze, Katowice, Poland
[2] Div Med Dent Zabrze, Zabrze, Poland
[3] Wroclaw Med, Chair & Clin Endocrinol Diabetol & Isotope Therap, Wroclaw, Poland
来源
CLINICAL DIABETOLOGY | 2016年 / 5卷 / 03期
关键词
diabetes; microRNA; treatment; molecular biology;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia, i.e. elevated blood sugar levels, which stems from a defect in production or action of insulin secreted by pancreatic beta cells. Type 2 diabetes, which involves reduced sensitivity of tissues to insulin, is the most common form of diabetes. Over the years knowledge concerning the etiology of both type 1 and type 2 diabetes was extended, which enabled implementation of new methods of treatment and prevention. Unfortunately, a monogenic factor conditioning the emergence of this disease still has not been isolated, hence scientists more often focus on regulators of expression of various metabolic proteins, e.g. miRNA, which are one of the more important factors regulating expression. First reports concerning the role of miRNA in metabolism in animal organisms come from observations of miR-14 mutants in fruit flies (Drosophila melanogaster). miRNA are single-stranded RNA molecules with a length of approx. 19-150 nucleotides. A single miRNA molecule can excite expression of several genes, inhibit it, or excite some and inhibit others. MicroRNA regulates the process of insulin secretion, cellular differentiation of beta cells in pancreatic islets and additionally influence glucose and lipid metabolism. All these issues are potential subjects of further research. Expansion of knowledge concerning microRNA and its role in disease processes is a target for devising new therapeutic strategy, and therefore utilization in production of drugs. Most research is currently in its initial phase, but even preliminary results are highly promising.
引用
收藏
页码:95 / 99
页数:5
相关论文
共 47 条
  • [1] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004)
    Bartel, David P.
    [J]. CELL, 2007, 131 (04) : 11 - 29
  • [2] Bednorz W., 2012, ENDOKRYNOLOGIA KLINI
  • [3] Microprocessor of microRNAs: regulation and potential for therapeutic intervention
    Beezhold, Kevin J.
    Castranova, Vince
    Chen, Fei
    [J]. MOLECULAR CANCER, 2010, 9
  • [4] RNA polymerase III transcribes human microRNAs
    Borchert, Glen M.
    Lanier, William
    Davidson, Beverly L.
    [J]. NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2006, 13 (12) : 1097 - 1101
  • [5] Caporali A, 2011, DEREGULATION MICRORN
  • [6] MicroRNA genetic variations: association with type 2 diabetes
    Ciccacci, Cinzia
    Di Fusco, Davide
    Cacciotti, Laura
    Morganti, Roberto
    D'Amato, Cinzia
    Greco, Carla
    Rufini, Sara
    Novelli, Giuseppe
    Sangiuolo, Federica
    Spallone, Vincenza
    Borgiani, Paola
    [J]. ACTA DIABETOLOGICA, 2013, 50 (06) : 867 - 872
  • [7] miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic β-cells
    El Ouaamari, Abdelfattah
    Baroukh, Nadine
    Martens, Geert A.
    Lebrun, Patricia
    Pipeleers, Daniel
    van Obberghen, Emmanuel
    [J]. DIABETES, 2008, 57 (10) : 2708 - 2717
  • [8] Therapeutic potential for microRNAs
    Esau, Christine C.
    Monia, Brett P.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (2-3) : 101 - 114
  • [9] Gavin JR, 1997, DIABETES CARE, V20, P1183
  • [10] Glebowska-Halawa H., 2012, ENDOKRYNOLOGIA KLINI